Jan 18, 2024
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Jan 04, 2024
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
Feb 23, 2021
Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism
Feb 08, 2021
Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 Published in Lancet Respiratory Medicine 2021
Jan 25, 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Jan 07, 2021
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
Nov 23, 2020
Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million
Nov 23, 2020
Proceeds from Priority Review Voucher Sale Will Fund Search for Cure for the Rapid Aging Disease Progeria
Nov 20, 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Nov 17, 2020
Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience(TM) 2020
Nov 16, 2020
Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience(TM) 2020
Nov 11, 2020
Eiger Bio to Participate in November 2020 Investor Conferences
Nov 02, 2020
Eiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience(TM) 2020
Oct 15, 2020
Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19
Sep 28, 2020
Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19
Sep 01, 2020
Eiger Bio to Participate in September 2020 Investor Conferences
Aug 31, 2020
Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress(TM) 2020
Aug 06, 2020
Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Aug 03, 2020
Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences
May 29, 2020
Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020